Sequential and AMILI Secure Prestigious $1.8M UK-Singapore Collaborative R&D Project to Advance Gut-Skin Microbiome Science
Chronic and recurrent ISDs affect 20-25% of the population, significantly impacting physical and mental well-being. Research has shown that the skin microbiome plays a crucial role in disease progression, with imbalances in the gut microbiota contributing extensively to ISD development. However, current microbiome testing services analyze the skin in isolation, failing to leverage the gut-skin axis for a comprehensive understanding of skin health.
Sequential has built a database of over 25,000 clinical skin microbiome samples and has pioneered the world's early skin microbiome at-home tests that were made commercially available in 2019. The previous recipient of an Innovate UK Smart Grant, with labs in US, Europe and Asia, Sequential is currently working with over 80 personal care and pharmaceutical companies innovating in the skin microbiome field.
AMILI, headquartered in Singapore, has been at the forefront of gut microbiome research. Since AMILI founders performed the first gut microbiome transplants in the region in 2014, AMILI has focused on developing and deeply analysing Asia's largest multi-ethnic gut microbiome database to map the relationships and mechanistic pathways between changes in the gut microbiome and health conditions.
This funding allows both organizations to accelerate their efforts in developing targeted, microbiome-driven interventions.
'We are thrilled to have won this competitive grant, which will enable us to pioneer a novel approach to further characterise inflammatory skin conditions,' said Dr. Oliver Worsley, CEO of Sequential. 'By leveraging our world-class skin microbiome dataset alongside AMILI's extensive gut microbiome research, we will be able to have a real impact by developing next generation, actionable and non-invasive at-home tests.'
'We thank both our countries for the faith in us. The gut-skin axis is a novel but clearly important dimension to improve diagnostic testing for the millions around the world afflicted with ISD and we in AMILI are delighted to work with Sequential on this exciting project' said Dr. Jeremy Lim, CEO of AMILI.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
'The air was so dangerous in my Birmingham postcode I ended up on life support'
A Birmingham resident who lived near the city's landmark motorway, the Spaghetti Junction, has revealed how she ended up on life support. Named only as Jenny, the 75-year-old woman said she 'never realised how dangerous the air was' until she was hospitalised with life-threatening pneumonia. Traffic fumes and poor housing conditions were to blame for her deteriorating health, doctors told her at the time. Living next to the busiest motorway in Europe, she also found herself suffering regular asthma attacks just from stepping outside. Read more: Couple who starved their dog told RSPCA inspectors she was 'given to them by drug dealers' The retiree found her health drastically improved when she moved nearer to green spaces and away from the motorway. Speaking as part of a new Health Equals campaign this week, she said: 'I never realised just how dangerous the air I was breathing every day really was, I used to live near Spaghetti Junction, and would suffer regular asthma attacks just from stepping outside my door. "It wasn't until I ended up in hospital with pneumonia and on life support that doctors told me the traffic fumes and my poor housing conditions were to blame. "Everyone deserves clean air – not just those lucky enough to live near green spaces or away from busy roads. My health improved dramatically after I moved and started walking in parks. But not everyone has that choice." Her experience with air pollution comes as Health Equals, a coalition of 85 organisations, revealed World Health Organisation (WHO) air quality guidelines were breached in 35,000 neighbourhoods across Britain. Its report also outlined all 506 schools in Birmingham were in neighbourhoods failing the guidelines, putting 290,000 children at risk of serious long term health problems, including heart disease and stroke. The new findings are being released as part of Health Equals' Make Health Equal campaign, to highlight alarming health inequalities: where toxic air, alongside other issues including poor income, unstable jobs and unsafe homes, are contributing to an alarming 16-year gap in life expectancy across the UK. Health Equals is calling for a cross-government strategy that prioritises action on these essential building blocks of health, to stop lives being cut short. City environment boss Coun Majid Mahmood said: "Poor air quality is a major risk to public health, and that is why we are committed to improving the city's air through our clean air strategy. 'Data published in October 2023 showed that our work to address the air pollutant, nitrogen dioxide, is delivering results, with pollution levels in Birmingham city centre slashed by almost 40 per centr since 2016, driven in part by the introduction of the Clean Air Zone. 'Across the city, a dedicated air quality monitoring programme of potential 'hotspots' in Birmingham has found that all sites are within the annual mean air quality objective. This three year monitoring project concluded in 2024 and sought to identify any locations where concentrations of nitrogen dioxide might exceed the annual mean air quality objective. I am pleased to confirm our evidence suggests that outside of the city centre area, air quality concentrations are within legal limits. 'We also monitor particulate matter, both coarse and fine fractions (PM10 and PM2.5), and all of our sites continue to show compliance with legal limits set by Government. We will continue to work with Government to further drive down concentrations of fine particles as we know these are the largest risk to health and we have extended our monitoring network to this end. 'This is supported by our mission to install year-round air monitoring equipment in schools a key component in this. These monitors come in tandem with accompanying education resources and lesson plans helping to inspire a new generation of Clean Air champions. Our work in this area is underpinned further by projects like 'Car Free School Streets', which seeks to reduce emissions during rush hour, driven by readings from council monitoring data showing that the school gates are among the most polluted parts of the city. 'The school sensor programme has the co-benefit of providing monitoring data for fine particulate matter, recognised as a key pollutant in a range of adverse health outcomes such as heart disease, lung diseases and cancers. 'Furthermore, surplus revenues from the Clean Air Zone are feeding directly into our transport plan, enabling us to work in partnership with the West Midlands Combined Authority to support schemes related to active travel, improve public transport infrastructure, and manage demand in the city centre. 'Projects funded by Clean Air Zone revenues include a trial of hydrogen buses, upgrades to the University railway station and new stations on the Camp Hill line, as well as a number of projects within the Cross-City Bus scheme, the expansion of the Car Free School Streets programme, and development of the next phase of the Birmingham Cycle Revolution. Community grants for projects delivering against our priorities have also been provided through the Environment and Transport Neighbourhoods Fund (ETNF). 'Our work towards our clean air objectives continues with the recent launch of a consultation into the renewal of the city's Smoke Control Order, offering greater powers of enforcement against those who breach guidelines. This is just the latest step in our journey, which will not stop until we have achieved our objective of clean air for all residents.' Have you been affected by this. We would like to hear from you. You can contact us by emailing us on
Yahoo
2 hours ago
- Yahoo
'Superstar' children in Southend raise more than £12,000 for cancer charity
YOUNGSTERS in Southend have raised more than £12,000 for a child cancer charity through a fun seafront fundraiser. The Gold Geese Goslings completed a charity fundraiser, with 150 children scooting, cycling or walking a seafront course at the from by Chalkwell Station. Gold Geese provides support for families fighting childhood cancer in south Essex, offering mental health therapy, treats, respite trips, help with hospital transport and food bills, and bereavement support. Go go go - The children set off on the seafront, walking, scooting and cycling. (Image: Kerry Green) Katie Southgate, Gold Geese founder and CEO, said: 'I absolutely loved seeing our gaggle of Goslings whizzing along the sea front and having a brilliant time, while raising so much money for local families facing childhood cancer. 'A special thank you to our Gold families who joined us on the day, our volunteers and to c2c for sponsoring the event, as well as our partners Brakes, PMS, Trophy Factory and Nisa - and to Kerry Green Photography for the fantastic photos. 'The donations raised by these superstar families mean we can be there for every local family fighting childhood cancer – thank you so much.' Fundraising - Gold Geese volunteers helped on the day. (Image: Kerry Green) More than £12,000 was raised from the day of fundraising, which will go directly towards supporting more families in south Essex struggling with childhood cancer. Each participant received a goody bag, Gold Geese t-shirt and medal to celebrate completing the fundraiser. Read more Fundraising appeal closes after raising £920k to improve cancer care in Southend Sister of Southend man who died at 19 from cancer riding 400 miles in memory Husband raises £13,500 for Southend Hospital appeal after wife's cancer diagnosis Well done - Medals awaited the children as they completed the route for charity. (Image: Kerry Green) Volunteers helped put the event together, supervising the children, laying out the route and putting the goody bags together. Hannah, mum to Louie, 1, who is currently living with cancer, said: 'Gold Geese saved me over and over again this past year. 'So many times I felt alone, scared and broken but they were always there. No judgement, no pressure, no stress just understanding and love. 'Whether it was a friendly catch up when I needed it the most, planned events for kids and adults, respite breaks away or food vouchers they continually saved me. 'I honestly don't know how I would have survived the past year without them - I will be forever grateful.' To donate to Gold Geese or learn the signs and symptoms of childhood cancer, visit
Yahoo
3 hours ago
- Yahoo
Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025
SHANGHAI and HONG KONG, July 27, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the 2025 European Society for Medical Oncology Annual Congress (ESMO 2025), taking place from October 17th to October 21st at the Messe Berlin in Berlin, Germany. Details of the Poster Presentation: ATG-022 (Claudin 18.2 antibody-drug conjugate)Title: Phase I/II study of Claudin 18.2 ADC ATG-022 in patients with advanced gastric/ gastroesophageal junction cancer (CLINCH)Abstract Number: 2907Presentation Number: 2113PDate: October 19, 2025 About ATG-022 ATG-022 is an antibody-drug conjugate (ADC) designed to target CLDN18.2, a member of the Claudin family of cell adhesion molecules. Under normal conditions, Claudins are located within tight junctions between cells, forming a barrier to regulate cell permeability. However, in cancer, Claudins are aberrantly expressed on the cell surface due to changes in cell polarity. CLDN18.2 is frequently overexpressed in a range of primary malignant tumors, including gastric, esophageal, cholangiocarcinoma, and pancreatic cancers. The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designations to ATG-022, for gastric and pancreatic cancers. Data from the ongoing CLINCH study demonstrated that ATG-022 delivers robust efficacy across all levels of CLDN18.2 expression in gastric cancer patients, including those with high, low, and ultra-low expression. This broad activity positions ATG-022 as a potential market leader, capable of addressing the largest patient population with CLDN18.2-positive tumors. Furthermore, the strong efficacy observed in patients with low CLDN18.2 expression suggests promise for treating other tumor types with similar expression profiles. About Antengene Antengene Corporation Limited ("Antengene", SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Mobile: +86 13062747000 View original content to download multimedia: SOURCE Antengene Corporation Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
